Journal article

Promoter hypomethylation of NY-ESO-1, association with clinicopathological features and PD-L1 expression in non-small cell lung cancer

Anderly C Chueh, Mun-Sem Liew, Prudence A Russell, Marzena Walkiewicz, Aparna Jayachandran, Maud HW Starmans, Paul C Boutros, Gavin Wright, Stephen A Barnett, John M Mariadason, Thomas John

ONCOTARGET | IMPACT JOURNALS LLC | Published : 2017

Abstract

Cancer-Testis antigens (CTA) are immunogenic molecules with normal tissue expression restricted to testes but with aberrant expression in up to 30% of non-small cell lung cancers (NSCLCs). Regulation of CTA expression is mediated in part through promoter DNA methylation. Recently, immunotherapy has altered treatment paradigms in NSCLC. Given its immunogenicity and ability to be re-expressed through demethylation, NY-ESO-1 promoter methylation, protein expression and its association with programmed death receptor ligand-1 (PD-L1) expression and clinicopathological features were investigated. Lung cancer cell line demethylation resulting from 5-Aza-2'-deoxycytidine treatment was associated wit..

View full abstract

Grants

Awarded by Pfizer Australia Cancer Grant


Funding Acknowledgements

This study was supported in part by Pfizer Australia Cancer Grant WI180223 (MSL), National Health and Medical Research Council Australia Postgraduate Scholarship (MSL); NHMRC Early Career Fellowship (TJ), Victorian Cancer Agency (TJ), Cancer Council Victoria (TJ), Ludwig Institute for Cancer Research (AC), Ontario Institute for Cancer Research (PCB), Terry Fox Research Institute New Investigator Award (PCB), CIHR New Investigator Award (PCB), and the Victorian Government operational infrastructure support program.